Climb Bio (CLYM)

• Market cap: $288M
• 1 day: 11.94%
• 5 days: -16.6%
• 1 month: -8.66%
• 3 months: 116.41%
• 6 months: 201.43%
• Year to date: 12.53%
• 1 year: 109.95%
• 5 years: -73.46%
• 10 years: -73.46%
• Sector: Healthcare
• Industry: Biotechnology

About: Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. its product candidate, budoprutug, is an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has the potential to treat a broad range of B-cell-mediated diseases.

Employees: 18